RhoVac ApS | LinkedIn

Press Release

Gunnar Gårdemyr new chairman of the board of RhoVac

Oct 30, 2019

RhoVac AB ("RhoVac") announces today, 30th October 2019, that Mikael Ørum will leave the board and the chair of the board, Gunnar Gårdemyr, who was elected to the board in May 2018, takes over as the chairman of the board.

Mikael Ørum comments: “First and foremost, I would like to thank management and the board for a result-oriented and professional collaboration. It has been very satisfying to be part of the very positive development that the company has undergone. I leave the board at a time when the company's management has been strengthened, the financial basis secured and the clinical phase IIb project launched. The reason for my resignation is that there is an increased need for me to prioritize Ventac Capital, which is a new life science fund with the aim of financing other exciting companies in Europe. It is with the utmost confidence that I entrust the chairmanship of a strong RhoVac to Gunnar Gårdemyr, with whom I have worked closely with the board in recent years. "

Gunnar Gårdemyr comments: “Rhovac is an exciting company with great commercial potential in the field of immunotherapy. The company has presented very promising data and there is a solid plan for the upcoming work. In addition, Rhovac has managed to attract highly qualified employees with a high level of commitment who consistently deliver according to plan. Rhovac addresses a major medical need in one of the most common types of cancer - prostate cancer - and the company has the opportunity to be the first company to prevent or limit prostate cancer metastases with immunotherapy. I look forward, together with the board and management, to pilot the company towards the next important clinical milestone". 

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is immediately launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study, which is expected to be completed in 2021, is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com